EA201890788A1 - Препараты оланзапина с замедленным высвобождением - Google Patents

Препараты оланзапина с замедленным высвобождением

Info

Publication number
EA201890788A1
EA201890788A1 EA201890788A EA201890788A EA201890788A1 EA 201890788 A1 EA201890788 A1 EA 201890788A1 EA 201890788 A EA201890788 A EA 201890788A EA 201890788 A EA201890788 A EA 201890788A EA 201890788 A1 EA201890788 A1 EA 201890788A1
Authority
EA
Eurasian Patent Office
Prior art keywords
olanzapin
preparations
delayed delivery
methods
pharmaceutically acceptable
Prior art date
Application number
EA201890788A
Other languages
English (en)
Inventor
Марк Алан Смит
Карин Классен-Пюнт
Original Assignee
Тева Фармасьютикалз Интернэшнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикалз Интернэшнл Гмбх filed Critical Тева Фармасьютикалз Интернэшнл Гмбх
Publication of EA201890788A1 publication Critical patent/EA201890788A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)

Abstract

Настоящее изобретение направлено на способы лечения шизофрении или биполярного расстройства путем подкожного введения лекарственной формы с замедленным высвобождением, содержащей оланзапин или его фармацевтически приемлемую соль. Также описываются способы подкожного введения оланзапина или его фармацевтически приемлемой соли.
EA201890788A 2015-09-21 2016-09-21 Препараты оланзапина с замедленным высвобождением EA201890788A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
EA201890788A1 true EA201890788A1 (ru) 2018-09-28

Family

ID=57047342

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890788A EA201890788A1 (ru) 2015-09-21 2016-09-21 Препараты оланзапина с замедленным высвобождением

Country Status (22)

Country Link
US (3) US20170079985A1 (ru)
EP (2) EP3352735B1 (ru)
JP (2) JP2018527397A (ru)
KR (1) KR20180054627A (ru)
CN (2) CN108289834A (ru)
AR (1) AR106085A1 (ru)
AU (2) AU2016328958B2 (ru)
CA (1) CA2998504C (ru)
CL (1) CL2018000727A1 (ru)
DK (1) DK3352735T3 (ru)
EA (1) EA201890788A1 (ru)
ES (1) ES2960753T3 (ru)
FI (1) FI3352735T3 (ru)
HK (1) HK1255946A1 (ru)
HU (1) HUE063850T2 (ru)
IL (3) IL295161A (ru)
MX (2) MX2018003380A (ru)
NZ (1) NZ740665A (ru)
PL (1) PL3352735T3 (ru)
PT (1) PT3352735T (ru)
TW (1) TWI798161B (ru)
WO (1) WO2017053346A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CA3087698A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
CZ300725B6 (cs) * 1997-09-30 2009-07-29 Eli Lilly And Company 2-Methylthienbenzodiazepinová formulace
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004016995D1 (de) 2003-06-26 2008-11-20 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
WO2005070332A1 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CN106075449A (zh) * 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
ES2531679T3 (es) 2006-07-11 2015-03-18 Foresee Pharmaceuticals, Inc. Composiciones para la administración de liberación controlada de péptidos
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
CA2683698C (en) 2007-04-19 2013-09-10 Hyun Hee Kwak A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
WO2009148580A2 (en) 2008-06-03 2009-12-10 Qlt Usa, Inc. Controlled release copolymer formulation with improved release kinetics
PT2323623T (pt) 2008-08-12 2016-11-04 Novartis Ag Composições farmacêuticas
JP5746629B2 (ja) 2008-10-10 2015-07-08 ポリアクティヴァ・プロプライエタリー・リミテッド 生分解性ポリマー−生物活性部分の複合体
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
ES2838012T3 (es) 2009-03-12 2021-07-01 Delpor Inc Dispositivo implantable durante un período largo de tiempo de fármacos
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
DK3536333T3 (da) 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
LT2394663T (lt) * 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
SI2717914T1 (sl) 2011-06-10 2020-07-31 Ramscor Inc. Formulacije z zadržanim sproščanjem za dostavo proteinov v oko in postopki njihove priprave
MX350469B (es) 2011-10-24 2017-09-07 Endo Pharmaceuticals Solutions Composiciones para el suministro de farmacos implantables y metodos para su tratamiento.
EP2806853B1 (en) 2012-01-23 2020-07-08 Allergan, Inc. Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6464154B2 (ja) 2013-06-20 2019-02-06 ファーマシェン エス．エー． Ｓ字型放出プロファイルを有するポリラクチド−ポリグリコリド微小粒子の調製
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
AR106085A1 (es) 2017-12-13
TWI798161B (zh) 2023-04-11
KR20180054627A (ko) 2018-05-24
WO2017053346A1 (en) 2017-03-30
NZ740665A (en) 2023-04-28
DK3352735T3 (da) 2023-10-30
US20180264001A1 (en) 2018-09-20
TW201726144A (zh) 2017-08-01
IL295161A (en) 2022-09-01
CN108289834A (zh) 2018-07-17
EP3352735A1 (en) 2018-08-01
HK1255946A1 (zh) 2019-09-06
IL258086A (en) 2018-05-31
EP4331570A1 (en) 2024-03-06
IL275735A (en) 2020-08-31
FI3352735T3 (fi) 2023-10-20
JP2018527397A (ja) 2018-09-20
MX2022007315A (es) 2022-07-13
US20170079985A1 (en) 2017-03-23
JP2021167331A (ja) 2021-10-21
EP3352735B1 (en) 2023-08-30
PT3352735T (pt) 2023-10-30
AU2016328958A1 (en) 2018-04-05
US20220323458A1 (en) 2022-10-13
CA2998504C (en) 2023-06-20
CN116942677A (zh) 2023-10-27
ES2960753T3 (es) 2024-03-06
CA2998504A1 (en) 2017-03-30
AU2016328958B2 (en) 2022-04-21
HUE063850T2 (hu) 2024-02-28
MX2018003380A (es) 2018-08-16
AU2022206695A1 (en) 2022-08-11
PL3352735T3 (pl) 2024-01-29
CL2018000727A1 (es) 2018-09-28

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
NZ760790A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
MX2019002541A (es) Derivados de pirimidina contra virus de la influenza.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
CY1123469T1 (el) Σχηματα δοσολογιας του melflufen για καρκινο
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201992832A1 (ru) Подкожное введение adamts13
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
EA201691741A1 (ru) Фармацевтическая композиция
MD20180049A2 (ru) Фармацевтическая композиция
MX2017008072A (es) Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.
EA201692531A1 (ru) Способы лечения инфекций
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.